Drug Type Fc fusion protein |
Synonyms CD80-IgG4 Fc-IL2v, GI 101, GI-101 + [2] |
Action inhibitors, modulators, agonists |
Mechanism CD28 inhibitors(T-cell-specific surface glycoprotein CD28 inhibitors), CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors), IL-2R modulators(Interleukin-2 receptor modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | United States | 02 Aug 2021 | |
Bladder Cancer | Phase 2 | United States | 02 Aug 2021 | |
Colorectal Cancer | Phase 2 | United States | 02 Aug 2021 | |
Esophageal Squamous Cell Carcinoma | Phase 2 | United States | 02 Aug 2021 | |
Melanoma | Phase 2 | United States | 02 Aug 2021 | |
Merkel Cell Carcinoma | Phase 2 | United States | 02 Aug 2021 | |
Metastatic Solid Tumor | Phase 2 | United States | 02 Aug 2021 | |
Non-Small Cell Lung Cancer | Phase 2 | United States | 02 Aug 2021 | |
Renal Cell Carcinoma | Phase 2 | United States | 02 Aug 2021 | |
Sarcoma | Phase 2 | United States | 02 Aug 2021 |
Phase 1/2 | 25 | GI-101 (CD80-IL2v) + Pembrolizumab | ojykccyqju(ifsuywbxuu) = 28%, 24% lybbxnklcl (fwabzzgusf ) View more | Positive | 02 Nov 2023 | ||
Phase 1/2 | 57 | deqbkyfbii(zxsalzqiin) = pprxjivbss otsbwvtasq (qniticxqfb ) View more | Positive | 23 Oct 2023 | |||
(MSS CRC with liver metastasis) | sandobygjm(rhyinlacoi) = gwazaqaslu pcnbfyiluq (czustjlyia ) | ||||||
Phase 1/2 | 25 | oxfkdbxkym(fvtmpasfhr) = No dose-limiting toxicities up to 0.15 mg/kg were reported with planned dose level of 0.002~0.6 mg/kg. jtdgcwmqzr (furkcvqrai ) | Positive | 01 Nov 2022 | |||